Clinical Trials Directory

Trials / Unknown

UnknownNCT05284162

Health Coaching Programme on Health Promoting Behaviours in Middle-Aged Adults With Cardiometabolic Risk

Effects of a Theory-guided Health Coaching Programme on Health Promoting Behaviours in Middle-Aged Adults With Cardiometabolic Risk: a Randomised Controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
202 (estimated)
Sponsor
Chinese University of Hong Kong · Academic / Other
Sex
All
Age
40 Years – 64 Years
Healthy volunteers
Accepted

Summary

Cardiometabolic disease has been an increasing trend globally and remains the major cause of morbidity and mortality in Hong Kong. Health coaching intervention are generally effective for managing chronic disease and prevention of complication. However, there is fewer attention on the effects of health coaching in primary disease prevention. This study aims to evaluate the effects of health coaching programme on increasing health promoting behaviours in middle-aged adults with cardiometabolic risk.

Detailed description

Cardiometabolic disease, including metabolic syndrome, prediabetes, type 2 diabetes mellitus, coronary heart disease, myocardial infarction and stroke, has been an increasing trend globally, and increased more than double over 5 years in China \[1\]. Cardiometabolic disease remains the major cause of morbidity and mortality in Hong Kong \[2\]. Type 2 diabetes mellitus is associated with increased risk for morbidity and mortality \[3\]. Ischaemic heart disease and stroke were the major cause of disability-adjusted life years (DALYs) worldwide, resulting in dependence, disability and cognitive impairment \[4\]. Moreover, midlife stroke risk is associated with cognitive decline within 10 years \[5\]. A local population health survey has reported that 41.1% of persons between the ages of 45 and 64 are at medium-to-high risk of developing cardiovascular diseases over the next 10 years \[6\]. Most of the cardiometabolic diseases are attributable to health behaviours. An international study identified risk factors for coronary heart disease and validated the non-laboratory INTERHEART Risk Score (IHRS), which is mainly calculated based on behavioural risk factors, including smoking, stress and physical activity \[7\]. Also, another study among 32 countries in Asia, Africa, Australia, Europe, the Middle East and USA reported that over 90% of the population attributable risks of stroke could be explained by behavioural risk factors measured by IHRS \[8\]. Proactive measures to moderate these modifiable risk factors are crucial to halt the increasing trend of cardiometabolic disease. Health coaching interventions are generally effective for managing chronic diseases, including cancer, heart disease, diabetes and hypertension \[9\]. A systematic review reported health coaching significantly increased physical activity, improved physical and mental health status in patients with chronic disease \[10\]. Health coaching interventions assist patients to participate actively in their health care, and health coaches collaborate with patients by giving support and promoting self-efficacy in disease management \[11\]. Despite the widespread use of evidence based health coaching in chronic disease management and prevention of complication, there is fewer attention on the effects of health coaching in primary disease prevention. Therefore, a large-scale, robust clinical trial examining the effects of health coaching in reducing the cardiometabolic risk in middle-aged adults is warranted. The purpose of this study is to address the research gap by evaluating the effects of health coaching programme on increasing health promoting behaviours in middle-aged adults with cardiometabolic risk.

Conditions

Interventions

TypeNameDescription
BEHAVIORALHealth coachingThe health coaching program includes four monthly health coaching sessions for three months.

Timeline

Start date
2021-04-01
Primary completion
2023-03-01
Completion
2023-03-01
First posted
2022-03-17
Last updated
2022-03-17

Locations

1 site across 1 country: Hong Kong

Source: ClinicalTrials.gov record NCT05284162. Inclusion in this directory is not an endorsement.